E-Mail
A new consortium of the EU Innovative Medicines Initiative (IMI) aims to establish the biggest database of pathology images to accelerate the development of artificial intelligence in medicine.
To take AI development in pathology to the next level, a European consortium combining leading European research centres, hospitals as well as major pharmaceutical industries, is going to develop a repository for the sharing of pathology data. The 6-year, €70 million project called BIGPICTURE, will herald a new era in pathology.
Pathology is the cornerstone of the workup of many diseases such as cancer, autoimmune diseases, of the follow up after transplantation and is also critical for the evaluation of the safety of drugs. It s based on the examination of tissue samples (slides) under the microscope. However, despite its pivotal role, it still relies heavily on the qualitative interpretation by a qualified pathologist.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global market for antibiotics should grow from $44.4 billion in 2020 to reach $65.4 billion by 2025 at a compound annual growth rate (CAGR) of 8.1% during the period of 2020-2025.
The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals, recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of non-branded generics.
The antibiotics market growth outlook is positive with significant growth potential for cell wall inhibitor and protein inhibitor antibiotic drugs. There is pressure on antibiotic drug manufacturers to offer antimicrobial-resistant drugs at affordable prices. At the same time, factors such as rising disposable incomes a
If the coronavirus pandemic and Europe-wide lockdowns taught us one thing, it is just how
reliant we all are on digital technologies – including for our own health, and that data was in the right place at the right time to answer the right questions.
Nigel Hughes is Scientific Director at Jannsen Research and Development (Johnson & Johnson), a Corporate Knowledge Partner of All Policies for a Healthy Europe.
Digital health can have a transformational impact on the well-being of EU citizens: from telemedicine enabling safe remote treatment of patients, to health data access allowing tracking and treatment of diseases, and Artificial Intelligence enhancing clinical decision-making. In April 2018, a European Commission Communication on the Transformation of Digital Health and Care stated the following: “Digital solutions for health and care can increase the wellbeing of millions of citizens and radically change the way health and care services are delivered to patients, if desi
Novartis International AG: Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
1
Detailed results will be submitted for publication to support scientific understanding of JAK inhibition in COVID-19 and inform ongoing research
Novartis commitment to address COVID-19 pandemic remains strong with multiple research collaboration initiatives ongoing
Basel, December 14, 2020 - Novartis today announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint
1. Initial data show there was no statistically significant reduction in the proportion of patients on ruxolitinib plus SoC therapy who experienced severe complications, including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit (ICU) by Day 29, compared to SoC alone
Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
Phase III study did not meet its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications (death, mechanical ventilation or ICU care)
1
Detailed results will be submitted for publication to support scientific understanding of JAK inhibition in COVID-19 and inform ongoing research
Novartis commitment to address COVID-19 pandemic remains strong with multiple research collaboration initiatives ongoing
Basel, December 14, 2020 Novartis today announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint